Stem cell factory opens door for trials of personalized diabetes treatment
By Andrew Joseph,
Stat News
| 06. 16. 2016
In a step that could lead to a new diabetes treatment, several Boston-area hospitals have teamed up with the Harvard Stem Cell Institute and biotech Semma Therapeutics to make personalized cell-based therapies and organize clinical trials.
It is one of several initiatives around the country aimed at manufacturing cell-derived treatments, as the hope for such therapies creates a demand for the production of the cells.
In patients with type 1 diabetes, the immune system attacks the pancreatic cells that produce insulin, called beta cells. Doctors have for years transplanted beta cells from dead donors into patients, but the supply is insufficient for the millions of people with type 1 diabetes, and patients’ bodies sometimes reject the donor cells.
Continue reading on STAT News
Image via Wikimedia
Related Articles
By Jennifer Denbow, Guest Contributor
| 10.29.2026
Almost every day I am reminded that we are in the midst of a fertility panic. Whether it’s the Vice President exhorting Americans to have more babies or The New York Times running yet another story about the fertility cliff, fear about falling fertility rates is everywhere. While centrally concerned with declining rates of childbearing, Anna Louie Sussman’s new book, Inconceivable: The Impossibility of Family in an Age of Uncertainty, is a welcome antidote to the panic.
Sussman has written...
By Anna Louie Sussman, The New Republic | 10.26.2026
There’s a certain kind of novel that’s not quite apocalyptic enough to be science fiction, but just far-fetched enough to be speculative. No one is from outer space; society has not yet been carved up into a hierarchy of groups...
By Ariana Aspuru and Noel King, Vox | 10.14.2026
For some couples, surrogacy is a miracle: an opportunity to have a child even if they’re unable to conceive one naturally. But it’s also big business. Not only is surrogacy expensive — think six figures — but it’s also largely...
By Sonia Suter and Naomi Cahn, The Conversation | 10.09.2026
